Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-08-01
1998-10-13
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 80, 514 81, 514214, 514249, 514300, 514303, 540487, 540500, 540502, 544337, 544349, 544350, 546 23, 546120, 546121, H61K 31495, H61K 3155, C07D47104, C07D48704
Patent
active
058212418
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/U.S. 94/01881, filed Feb. 22, 1994.
BACKGROUND OF THE INVENTION
The invention relates generally to modulating cell adhesion and to inhibiting the binding of fibrinogen and other proteins to blood platelets, and inhibiting the aggregation of blood platelets specifically to the IIb/IIIa fibrinogen receptor site. Fibrinogen is a glycoprotein present in blood plasma that participates in platelet aggregation and in fibrin formation. Platelets are cell-like anucleated fragments, found in the blood of all mammals, that also participate in blood coagulation. Interaction of fibrinogen with the IIb/IIIa receptor site is known to be essential for normal platelet function.
When a blood vessel is damaged by an injury or other causative factor, platelets adhere to the disrupted subendothethial surface. The adherent platelets subsequently release biologically active constituents and aggregate. Aggregation is initiated by the binding of agonists, such as thrombin, epinephrine, or ADP to specific platelet membrane receptors. Stimulation by agonists results in exposure of latent fibrinogen receptors on the platelet surface, and binding of fibrinogen to the glycoprotein IIb/IIIa receptor complex.
Attempts have been made to use natural products and synthetic peptides to determine the mechanism of adhesion and platelet aggregation. For example, Rouslahti and Pierschbacher in Science, 238, 491-497 (1987), describe adhesive proteins such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, fibrinogen, and von Willebrand factor that are present in extracellular matrices and in blood. The proteins contain the tripeptide arginine-glycine-aspartic acid (RGD) as their glycoprotein IIb/IIIa recognition site. These arginine-glycine-aspartic acid containing tripeptides are recognized by at least one member of a family of structurally related receptors, integrins, which are heterodimeric proteins with two membrane-spanning subunits. The authors state that the conformation of the tripeptide sequence in the individual proteins may be critical to recognition specificity.
Cheresh in Proc. Nat'l Acad. Sci. U.S.A., 84, 6471-6475, (1987), describes an Arg-Gly-Asp directed adhesion receptor expressed by human endothelial cells that is structurally similar to the IIb/IIIa complex on platelets but is antigenically and functionally distinct. This receptor is directly involved in endothelial cell attachment to fibrinogen, von Willebrand factor, and vitronectin.
Pierschbacher and Rouslahti, in J. of Biol. Chem., 262, (36), 17294-17298 (1987) hypothesized that the Arg-Gly-Asp sequence alone would be a sufficient signal for receptor recognition and binding and that, therefore, the conformation of the tri-peptide sequence would be determinative. Various synthetic peptides were produced and the authors concluded that the stereochemical conformation of Arg-Gly-Asp as influenced by enantiomeric substitutions or additions to this sequence significantly influenced receptor-ligand interaction. The authors further showed that cyclization of a decapeptide by forming a disulfide bridge between non-terminal residues Pen and Cys, rendered the peptide much less effective at inhibiting attachment to fibronectin.
In Proc. Nat'l Acad. Sci. U.S.A., 81, 5985-5988 (1984), the same authors describe tetrapeptide variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Peptides having a tetrapeptide recognition site are described in U.S. Pat. Nos. 4,589,881 and 4,614,517. A number of large polypeptide fragments in the cellbinding domain of fibronectin have cell-attachment activity. For example, see U.S. Pat. Nos. 4,517,686, 4,661,111 and U.S. Pat. No. 4,578,079.
Ruggeri et al., Proc. Nat'l Acad. Sci. U.S.A., 83, 5708-5712 (1986) explore a series of synthetic peptides designed in lengths to 16 residues, that contain RGD and a valine attached to the aspartic acid residue of RGD that inhibit fibrinogen binding to platelets. See also Koczewiak et al., Biochem. 23, 1767-1774 (1984); Ginsbe
REFERENCES:
patent: 3322631 (1967-05-01), Sprague et al.
patent: 4010274 (1977-03-01), Giraldi et al.
patent: 4122255 (1978-10-01), Krapcho
patent: 4243807 (1981-01-01), Friebe et al.
patent: 4313947 (1982-02-01), Nakagawa et al.
patent: 4622331 (1986-11-01), Jozic
patent: 5030654 (1991-07-01), Barnish et al.
patent: 5095018 (1992-03-01), Kelley
patent: 5166154 (1992-11-01), Skiles et al.
patent: 5227490 (1993-07-01), Hartman et al.
patent: 5260316 (1993-11-01), Van Duzer et al.
patent: 5264420 (1993-11-01), Duggan et al.
patent: 5272158 (1993-12-01), Hartman et al.
patent: 5278161 (1994-01-01), Branca et al.
patent: 5281585 (1994-01-01), Duggan et al.
patent: 5292756 (1994-03-01), Duggan et al.
patent: 5294616 (1994-03-01), Duggan et al.
patent: 5321034 (1994-06-01), Duggan et al.
Sugimoto et al., "7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1(2H)-phthalazinone Derivatives: Synthesis and Inhibitory Effects on Platelet Aggregation", J. Med. Chem., vol. 27, pp. 1300-1305 (1984).
Askew Ben
Baldwin John J.
Claremon David Alan
Liverton Nigel
Merck & Co. , Inc.
Parr Richard S.
Raymond Richard L.
Winokur Melvin
LandOfFree
Fibrinogen receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibrinogen receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrinogen receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-313385